Therapy Areas: Hereditary Disorders
Spyryx Biosciences Adds Roger Jeffs, PhD as Independent Director
19 January 2018 - - US-based clinical-stage biopharmaceutical company Spyryx Biosciences, Inc. has elected Dr. Roger Jeffs as a member of its board of directors, the company said.
Jeffs brings over 25 years of biopharmaceutical industry experience, including 18 years at United Therapeutics where he retired in 2016 as president and co-CEO.
At United Therapeutics, Jeffs led the clinical development, regulatory approval, and commercialization of six rare disease products and managed the commercial effort that produced USD1.5 bn in annual revenue.
Prior to United Therapeutics, he held positions in clinical development at Amgen and Burroughs Wellcome.
Jeffs currently serves as a member of the board of directors of 4 public biopharma companies: Albireo Pharma, Axsome Therapeutics, Dova Pharmaceuticals, and Sangamo Therapeutics.
Spyryx Biosciences is developing innovative therapeutics to address severe pulmonary diseases. Its lead clinical candidate, SPX-101, is completing a multinational Phase 2 study as a novel treatment for cystic fibrosis.
The company is funded by a first-tier syndicate of life science investors, including Canaan Partners, 5AM Ventures, and Hatteras Venture Partners.
Login
Username:

Password:


Related Headlines

Vertex Pharmaceuticals receives European Commission approval for ORKAMBI (lumacaftor/ivacaftor) To treat children with cystic fibrosis aged 1 to <2 years old

cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial

Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment with CFTR Modulators at the European Cystic Fibrosis Conference

First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study

Vertex Receives FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes

Aluna Raises USD 15.3m in Series B Funding

First Patient Dosed in Adaptive Phage Therapeutics' PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory Infection

CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy

Markels Named to Arcturus Therapeutics Board of Directors

SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis

Sionna Therapeutics receives approval from US Food and Drug Administration for Investigational New Drug application of SION-638

Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines

Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera